BrainChild
BrainChild develops locoregional CAR T cell therapies for pediatric brain tumors, including treatments delivered directly into the cerebrospinal fluid to bypass the blood-brain barrier. Its mission is to improve outcomes for children with deadly brain cancers.
Facts
- HQ
- Seattle
- Sectors
- Biotech, Healthcare, Cell therapy, Immunotherapy
- Founded
- 2023
Is this your organization? Claim it
Recent coverage
Front-page news, podcasts and videos about BrainChild
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
Questions about BrainChild
What is BrainChild?
Seattle
Where is BrainChild based?
BrainChild is headquartered in Seattle.
When was BrainChild founded?
BrainChild was founded in 2023.